Presentation

At Neurolixis we believe that a key to success is to build a tightly-knit team of creative individuals with demonstrated track records of achievement in fundamental research, target validation, drug discovery and development.

Our Management Team and Scientific Advisory Board reflect this belief and lay the foundations for building our drug discovery and clinical development projects.

In addition, Neurolixis has built an extensive network of research collaborations with top-level international academic research groups. These collaborations reinforce Neurolixis' position as a leading science-driven bioscience company. See the Publications that have been generated through these collaborations.

 

Dr. Christopher Jankosky, MD, MPH

 
Dr. Jankosky, MD, MPH, is board certified in both Neurology and Occupational & Environmental Medicine.  In 2018 he founded and grew his medical consulting practice, serving as the Corporate Medical Advisor for multiple Fortune 500 companies, and engaging in entrepreneurial ventures that maintained his expertise focusing on the interplay of neurology and the environment. Prior to that, Dr. Jankosky held critical leadership positions at the FDA, serving as an expert in vaccines and gene therapies for 5 years and receiving the Center for Biologics Managerial Excellence Award. He is a retired Navy Captain, whose executive physician positions included Director of the largest Occupational & Environmental Medicine Residency training program in the nation, as well as the Force Surgeon for the U.S. Pacific Submarine Force. He was tasked by the U.S. government to lead health-related engagements in locations as diverse as Vietnam, Ukraine, the Peruvian Amazon, Australia, and Antarctica. He maintains adjunct faculty appointments at the University of Maryland and the Uniformed Services University.

Pipeline

Development of early-stage clinical and pre-clinical assets:

Neurolixis is developing a platform of early-stage drug candidates targeting serious CNS diseases with unmet medical needs and sizeable market opportunity. Compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism" which enables drugs to more precisely target specific brain regions controlling CNS disorders.

NLX-112, is undergoing a Phase 2A study for the treatment of movement disorders, notably L-DOPA-induced dyskinesia, a side-effect of Parkinson's disease treatment.

NLX-101, is a Phase I drug intended for treatment of autism spectrum disorders such as Rett's syndrome and Fragile X syndrome, serious genetically-encoded orphan disorders. 

NLX-204 is the lead novel chemical entity from the drug discovery program. It is a candidate for development as a potential rapid-acting antidepressant or analgesic (non-opioid mechanism).

 

All drugs or therapies will be subjected to rigorous testing under applicable law and approval by regulatory authorities, including the FDA, prior to marketing and sale.

Therapeutic Focus

Neurolixis Inc. is focused on pre-clinical drug discovery and early clinical development of candidates targeting unmet needs in the field of neurological and neuropsychiatric illness. Priority clinical programs target Parkinson's disease and Rett syndrome.
In addition, Neurolixis pursues drug discovery projects targeting mood disorders and cognitive deficits, which are a debilitating feature of CNS diseases and often exhibit treatment resistance to currently-available treatments.

 

Parkinson's disease

Parkinson's disease (PD) is one of the most common nervous system disorders of the elderly. The movement-related symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise whereas depression is the most common psychiatric symptom. Prolonged treatment with the antiparkinsonian drug, L-DOPA, elicits dyskinesia as a side-effect. Neurolixis is developing NLX-112 to alleviate this. More...

 

Rett syndrome

Rett syndrome (RTT) is a severely debilitating, genetically-encoded orphan disorder that occurs almost exclusively in females and is characterized by arrested development between 6 and 18 months of age, regression of acquired skills, loss of speech, seizures, and mental retardation. Among the symptoms of RTT, dysrhythmic breathing, cognitive deficits and movement difficulties are particularly disturbing and Neurolixis is developing NLX-101 to treat RTT. More...

 

Company

Neurolixis Inc. is an early-stage biopharmaceutical company developing novel treatments for disorders of the central nervous system. Neurolixis is advancing its drug discovery and development programs and has a promising drug development pipeline:

 

Therapeutic focus

Neurolixis exploits novel neuronal mechanisms to improve therapy of serious central nervous system disorders, including Parkinson's disease, Rett syndrome, depression and pain. More...

Pipeline

Neurolixis is developing in-licensed early clinical assets with innovative profiles (NLX-112 and NLX-101) and also identifying and developing proprietary Novel Chemical Entities (NCEs). More...

Publications

Neurolixis places high value on pharmacological target validation. Studies describing its clinical assets have been published in peer-reviewed journals. More...

  1. Home Page statement

Page 2 of 2

Follow Neurolixis on: